Predictors of urinary morbidity in Cs-131 prostate brachytherapy implants.

  title={Predictors of urinary morbidity in Cs-131 prostate brachytherapy implants.},
  author={Russell P. Smith and Heather Ann Jones and Sushil Beriwal and Abhay S. Gokhale and Ronald M. Benoit},
  journal={International journal of radiation oncology, biology, physics},
  volume={81 3},
PURPOSE Cesium-131 is a newer radioisotope being used in prostate brachytherapy (PB). This study was conducted to determine the predictors of urinary morbidity with Cs-131 PB. METHODS AND MATERIALS A cohort of 159 patients underwent PB with Cs-131 at our institution and were followed by using Expanded Prostate Cancer Index Composite (EPIC) surveys to determine urinary morbidity over time. EPIC scores were obtained preoperatively and postoperatively at 2 and 4 weeks, and 3 and 6 months… CONTINUE READING